Skip to main content
Top
Published in: BMC Infectious Diseases 1/2014

Open Access 01-12-2014 | Case report

Clinical features and management of a severe paradoxical reaction associated with combined treatment of Buruli ulcer and HIV co-infection

Authors: Franck Wanda, Patrick Nkemenang, Genevieve Ehounou, Marie Tchaton, Eric Comte, Laurence Toutous Trellu, Isabelle Masouyé, Vanessa Christinet, Daniel P O’Brien

Published in: BMC Infectious Diseases | Issue 1/2014

Login to get access

Abstract

Background

In West and Central Africa Buruli ulcer (BU) and HIV co-infection is increasingly recognised and management of these two diseases combined is an emerging challenge for which there is little published information. In this case we present a severe paradoxical reaction occurring after commencing antibiotic treatment for BU combined with antiretroviral therapy for HIV, and describe its clinical features and management. This includes to our knowledge the first reported use of prednisolone in Africa to manage a severe paradoxical reaction related to BU treatment.

Case presentation

A 30 year old immunosuppressed HIV positive man from Cameroon developed a severe paradoxical reaction 24 days after commencing antibiotic treatment for BU and 14 days after commencing antiretroviral therapy for HIV. Oral prednisolone was successfully used to settle the reaction and prevent further tissue loss. The antiretroviral regimen was continued unchanged and the BU antibiotic treatment not prolonged beyond the recommended duration of 8 weeks. A second small local paradoxical lesion developed 8 months after starting antibiotics and settled with conservative treatment only. Complete healing of lesions occurred and there was no disease recurrence 12 months after commencement of treatment.

Conclusions

Clinicians should be aware that severe paradoxical reactions can occur during the treatment of BU/HIV co-infected patients. Prednisolone was effectively and safely used to settle the reaction and minimize the secondary tissue damage.
Appendix
Available only for authorised users
Literature
1.
go back to reference World Health Organisation: Treatment of Mycobacterium Ulcerans Disease (Buruli ulcer): Guidance for Health Workers. 2012, Geneva, Switzerland World Health Organisation: Treatment of Mycobacterium Ulcerans Disease (Buruli ulcer): Guidance for Health Workers. 2012, Geneva, Switzerland
2.
go back to reference Christinet V, Rossel L, Serafini M, Delhumeau C, Odermatt P, Ciaffi L: Impact of HIV on the Severity of Buruli Ulcer Disease: Results from a Retrospective Study in Cameroon. Open Forum Infect Dis. 2014, 1: 1-CrossRef Christinet V, Rossel L, Serafini M, Delhumeau C, Odermatt P, Ciaffi L: Impact of HIV on the Severity of Buruli Ulcer Disease: Results from a Retrospective Study in Cameroon. Open Forum Infect Dis. 2014, 1: 1-CrossRef
3.
go back to reference Johnson RC, Nackers F, Glynn JR, de Biurrun Bakedano E, Zinsou C, Aguiar J, Tonglet R, Portaels F, Johnson RC, Nackers F, Glynn JR, de Biurrun Bakedano E, Zinsou C, Aguiar J, Tonglet R, Portaels F: Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS (London, England). 2008, 22 (7): 901-903.CrossRef Johnson RC, Nackers F, Glynn JR, de Biurrun Bakedano E, Zinsou C, Aguiar J, Tonglet R, Portaels F, Johnson RC, Nackers F, Glynn JR, de Biurrun Bakedano E, Zinsou C, Aguiar J, Tonglet R, Portaels F: Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS (London, England). 2008, 22 (7): 901-903.CrossRef
4.
go back to reference Kibadi K, Colebunders R, Muyembe-Tamfum JJ, Meyers WM, Portaels F: Buruli ulcer lesions in HIV-positive patient. Emerg Infect Dis. 2010, 16 (4): 738-739.CrossRefPubMedPubMedCentral Kibadi K, Colebunders R, Muyembe-Tamfum JJ, Meyers WM, Portaels F: Buruli ulcer lesions in HIV-positive patient. Emerg Infect Dis. 2010, 16 (4): 738-739.CrossRefPubMedPubMedCentral
5.
go back to reference Nienhuis WA, Stienstra Y, Abass KM, Tuah W, Thompson WA, Awuah PC, Awuah-Boateng NY, Adjei O, Bretzel G, Schouten JP, van der Werf TS: Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis. 2012, 54 (4): 519-526.CrossRefPubMed Nienhuis WA, Stienstra Y, Abass KM, Tuah W, Thompson WA, Awuah PC, Awuah-Boateng NY, Adjei O, Bretzel G, Schouten JP, van der Werf TS: Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis. 2012, 54 (4): 519-526.CrossRefPubMed
6.
go back to reference O’Brien DP, Robson M, Friedman ND, Walton A, McDonald A, Callan P, Hughes A, Rhadon R, Athan E: Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections. BMC Infect Dis. 2013, 13: 416-CrossRefPubMedPubMedCentral O’Brien DP, Robson M, Friedman ND, Walton A, McDonald A, Callan P, Hughes A, Rhadon R, Athan E: Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections. BMC Infect Dis. 2013, 13: 416-CrossRefPubMedPubMedCentral
7.
go back to reference Friedman ND, McDonald A, Robson M, O’Brien DP: Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans. PLoS Neglected Trop Dis. 2012, 6 (9): e1769-CrossRef Friedman ND, McDonald A, Robson M, O’Brien DP: Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans. PLoS Neglected Trop Dis. 2012, 6 (9): e1769-CrossRef
8.
go back to reference O’Brien DP, Comte E, Serafini M, Ehounou G, Antierens A, Vuagnat H, Christinet V, Hamani MD, du Cros P: The urgent need for clinical, diagnostic, and operational research for management of Buruli ulcer in Africa. Lancet Infect Dis. 2014, 14 (5): 435-440.CrossRefPubMed O’Brien DP, Comte E, Serafini M, Ehounou G, Antierens A, Vuagnat H, Christinet V, Hamani MD, du Cros P: The urgent need for clinical, diagnostic, and operational research for management of Buruli ulcer in Africa. Lancet Infect Dis. 2014, 14 (5): 435-440.CrossRefPubMed
9.
go back to reference O’Brien DP, Robson ME, Callan PP, McDonald AH: “Paradoxical” immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust. 2009, 191 (10): 564-566.PubMed O’Brien DP, Robson ME, Callan PP, McDonald AH: “Paradoxical” immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust. 2009, 191 (10): 564-566.PubMed
10.
go back to reference Phillips R, Sarfo FS, Guenin-Mace L, Decalf J, Wansbrough-Jones M, Albert ML, Demangel C: Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. J Infect Dis. 2009, 200 (11): 1675-1684.CrossRefPubMed Phillips R, Sarfo FS, Guenin-Mace L, Decalf J, Wansbrough-Jones M, Albert ML, Demangel C: Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. J Infect Dis. 2009, 200 (11): 1675-1684.CrossRefPubMed
11.
go back to reference Schutte D, Pluschke G: Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). Expet Opin Biol Ther. 2009, 9 (2): 187-200.CrossRef Schutte D, Pluschke G: Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). Expet Opin Biol Ther. 2009, 9 (2): 187-200.CrossRef
12.
go back to reference Ruf MT, Chauty A, Adeye A, Ardant MF, Koussemou H, Johnson RC, Pluschke G: Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?. PLoS Neglected Trop Dis. 2011, 5 (8): e1252-CrossRef Ruf MT, Chauty A, Adeye A, Ardant MF, Koussemou H, Johnson RC, Pluschke G: Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?. PLoS Neglected Trop Dis. 2011, 5 (8): e1252-CrossRef
13.
go back to reference Beissner M, Piten E, Maman I, Symank D, Jansson M, Nitschke J, Amekuse K, Kobara B, Wiedemann F, Hoffmann H, Diefenhardt A, Badziklou K, Banla Kere A, Loscher T, Bretzel G: Spontaneous clearance of a secondary Buruli ulcer lesion emerging ten months after completion of chemotherapy–a case report from Togo. PLoS Neglected Trop Dis. 2012, 6 (7): e1747-CrossRef Beissner M, Piten E, Maman I, Symank D, Jansson M, Nitschke J, Amekuse K, Kobara B, Wiedemann F, Hoffmann H, Diefenhardt A, Badziklou K, Banla Kere A, Loscher T, Bretzel G: Spontaneous clearance of a secondary Buruli ulcer lesion emerging ten months after completion of chemotherapy–a case report from Togo. PLoS Neglected Trop Dis. 2012, 6 (7): e1747-CrossRef
14.
go back to reference Tansuphasawadikul S, Saito W, Kim J, Phonrat B, Dhitavat J, Chamnachanan S, Pitisuttithum P: Outcomes in HIV-infected patients on antiretroviral therapy with tuberculosis. Southeast Asian J Trop Med Publ Health. 2007, 38 (6): 1053-1060. Tansuphasawadikul S, Saito W, Kim J, Phonrat B, Dhitavat J, Chamnachanan S, Pitisuttithum P: Outcomes in HIV-infected patients on antiretroviral therapy with tuberculosis. Southeast Asian J Trop Med Publ Health. 2007, 38 (6): 1053-1060.
15.
go back to reference Chang CC, Dorasamy AA, Gosnell BI, Elliott JH, Spelman T, Omarjee S, Naranbhai V, Coovadia Y, Ndung’u T, Moosa MY, ILewin SR, French MA: Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome. AIDS (London, England). 2013, 27 (13): 2089-2099.CrossRef Chang CC, Dorasamy AA, Gosnell BI, Elliott JH, Spelman T, Omarjee S, Naranbhai V, Coovadia Y, Ndung’u T, Moosa MY, ILewin SR, French MA: Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome. AIDS (London, England). 2013, 27 (13): 2089-2099.CrossRef
16.
go back to reference Phillips P, Bonner S, Gataric N, Bai T, Wilcox P, Hogg R, O’Shaughnessy M, Montaner J: Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis. 2005, 41 (10): 1483-1497.CrossRefPubMed Phillips P, Bonner S, Gataric N, Bai T, Wilcox P, Hogg R, O’Shaughnessy M, Montaner J: Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis. 2005, 41 (10): 1483-1497.CrossRefPubMed
17.
go back to reference Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M, Ie DEAS, Central A: Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010, 10 (4): 251-261.CrossRefPubMedPubMedCentral Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M, Ie DEAS, Central A: Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010, 10 (4): 251-261.CrossRefPubMedPubMedCentral
18.
go back to reference Komenan K, Elidje EJ, Ildevert GP, Yao KI, Kanga K, Kouame KA, Abdoulaye S, Hamdam KS, Yao YP, Jean-Marie K: Multifocal Buruli ulcer associated with secondary infection in HIV positive Patient. Case Rep Med. 2013, 2013: 348628-PubMedPubMedCentral Komenan K, Elidje EJ, Ildevert GP, Yao KI, Kanga K, Kouame KA, Abdoulaye S, Hamdam KS, Yao YP, Jean-Marie K: Multifocal Buruli ulcer associated with secondary infection in HIV positive Patient. Case Rep Med. 2013, 2013: 348628-PubMedPubMedCentral
19.
go back to reference Martins TG, Trigo G, Fraga AG, Gama JB, Longatto-Filho A, Saraiva M, Silva MT, Castro AG, Pedrosa J: Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection. PLoS Neglected Trop Dis. 2012, 6 (11): e1925-CrossRef Martins TG, Trigo G, Fraga AG, Gama JB, Longatto-Filho A, Saraiva M, Silva MT, Castro AG, Pedrosa J: Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection. PLoS Neglected Trop Dis. 2012, 6 (11): e1925-CrossRef
20.
go back to reference Trevillyan JM, Johnson PD: Steroids control paradoxical worsening of Mycobacterium ulcerans infection following initiation of antibiotic therapy. Med J Aust. 2013, 198 (8): 443-444.CrossRefPubMed Trevillyan JM, Johnson PD: Steroids control paradoxical worsening of Mycobacterium ulcerans infection following initiation of antibiotic therapy. Med J Aust. 2013, 198 (8): 443-444.CrossRefPubMed
21.
go back to reference O’Brien DP, Jenkin G, Buntine J, Steffen CM, McDonald A, Horne S, Friedman ND, Athan E, Hughes A, Callan PP, Johnson PD: Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update. Med J Aust. 2014, 200 (5): 267-270.CrossRefPubMed O’Brien DP, Jenkin G, Buntine J, Steffen CM, McDonald A, Horne S, Friedman ND, Athan E, Hughes A, Callan PP, Johnson PD: Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update. Med J Aust. 2014, 200 (5): 267-270.CrossRefPubMed
22.
go back to reference Friedman ND, Athan E, Hughes AJ, Khajehnoori M, McDonald A, Callan P, Rahdon R, O’Brien DP: Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort. PLoS Neglected Trop Dis. 2013, 7 (7): e2315-CrossRef Friedman ND, Athan E, Hughes AJ, Khajehnoori M, McDonald A, Callan P, Rahdon R, O’Brien DP: Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort. PLoS Neglected Trop Dis. 2013, 7 (7): e2315-CrossRef
23.
go back to reference Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, Adeye A, Goundote A, Cottin J, Ladikpo T, Ruf T, Ji B: Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis. 2011, 52 (1): 94-96.CrossRefPubMed Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, Adeye A, Goundote A, Cottin J, Ladikpo T, Ruf T, Ji B: Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis. 2011, 52 (1): 94-96.CrossRefPubMed
24.
go back to reference O’Brien DP, Comte E, Ford N, Christinet V, du Cros P: Moxifloxacin for Buruli ulcer/HIV coinfected patients: kill two birds with one stone?. AIDS (London, England). 2013, 27 (14): 2177-2179.CrossRef O’Brien DP, Comte E, Ford N, Christinet V, du Cros P: Moxifloxacin for Buruli ulcer/HIV coinfected patients: kill two birds with one stone?. AIDS (London, England). 2013, 27 (14): 2177-2179.CrossRef
Metadata
Title
Clinical features and management of a severe paradoxical reaction associated with combined treatment of Buruli ulcer and HIV co-infection
Authors
Franck Wanda
Patrick Nkemenang
Genevieve Ehounou
Marie Tchaton
Eric Comte
Laurence Toutous Trellu
Isabelle Masouyé
Vanessa Christinet
Daniel P O’Brien
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-14-423

Other articles of this Issue 1/2014

BMC Infectious Diseases 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.